Topical Acne Products

Policy # 00343
Original Effective Date: 02/20/2013
Current Effective Date: 03/21/2018

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

For Patients With “Step Therapy” (generic before brand) ONLY:
Based on review of available data, the Company may consider brand name topical acne products including, but not limited to products containing dapsone (e.g., Aczone®)
‡, azelaic acid (e.g., Azelex®)
‡, benzoyl peroxide (e.g., Zoderm®, Benziq®)
‡, sulfacetamide (e.g., Klaron®, sulfacetamide/sulfur (e.g., Avar®, Zetacel®
†), clindamycin (e.g., Clindets®, Evoclin®)
‡, and combinations of these products (e.g., Benzamycin PAK®, Inova®, Aktipak™, Epiduo®)
‡ to be eligible for coverage when the patient selection criteria are met:

Patient Selection Criteria
Coverage eligibility will be considered for brand name topical acne products when ALL of the specific drug’s criteria are met:

• The patient has tried and failed one generic prescription topical adapalene, benzoyl peroxide, clindamycin, erythromycin, or sodium sulfacetamide containing product; OR
• There is clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of brand name topical acne products when patient selection criteria are not met or for usage not included in the above patient selection criteria to be not medically necessary.**

For Patients With “Prior Authorization” ONLY:
Based on review of available data, the Company may consider Aktipak (erythromycin/benzoyl peroxide) to be eligible for coverage when the patient selection criteria are met:

Patient Selection Criteria
Coverage eligibility will be considered for Aktipak (erythromycin/benzoyl peroxide) when the following criteria are met:

• The drug will be used for topical treatment of acne vulgaris; AND
• The patient has tried and failed (e.g., intolerance or inadequate response) an over the counter benzoyl peroxide product for at least one month unless there is clinical evidence or patient history that suggests the use of this product will be ineffective or cause an adverse reaction to the patient; AND

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of Aktipak (erythromycin/benzoyl peroxide) when the patient has not tried and failed an over the counter benzoyl peroxide product for at least one month AND a separate benzoyl peroxide product and generic topical clindamycin or erythromycin product used together for at least one month AND a generic combination erythromycin/benzoyl peroxide gel or generic combination clindamycin/benzoyl peroxide gel for at least one month to be not medically necessary.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of Aktipak (erythromycin/benzoyl peroxide) for any indication other than for the treatment of acne vulgaris to be investigational.

For Patients With BOTH “Prior Authorization” AND “Step Therapy”:
Based on review of available data, the Company may consider brand name topical acne products including, but not limited to products containing dapsone (e.g., Aczone), azelaic acid (e.g., Azelex), benzoyl peroxide (e.g., Zoderm, Benziq), sulfacetamide (e.g., Klaron), sulfacetamide/sulfur (e.g., Avar, Zetacet), clindamycin (e.g., Clindets, Evoclin), and combinations of these products (e.g., Benzamycin PAK, Inova, Aktipak, Epiduo) to be eligible for coverage when the patient selection criteria are met:

Patient Selection Criteria
Coverage eligibility will be considered for brand name topical acne products when ALL of the specific drug’s criteria are met for the requested drug:

- For Aktipak requests ONLY:
  o The drug will be used for topical treatment of acne vulgaris; AND
Topical Acne Products

Policy # 00343
Original Effective Date: 02/20/2013
Current Effective Date: 03/21/2018

- The patient has tried and failed (e.g., intolerance or inadequate response) an over the counter benzoyl peroxide product for at least one month unless there is clinical evidence or patient history that suggests the use of this product will be ineffective or cause an adverse reaction to the patient; AND
- The patient has tried and failed (e.g., intolerance or inadequate response) a separate benzoyl peroxide product AND generic topical clindamycin or erythromycin product used together for at least one month unless there is clinical evidence or patient history that suggests the use of these products will be ineffective or cause an adverse reaction to the patient; AND
- The patient has tried and failed (e.g., intolerance or inadequate response) generic combination erythromycin-benzoyl peroxide gel or generic combination clindamycin-benzoyl peroxide gel for at least one month unless there is clinical evidence or patient history that suggests the use of these products will be ineffective or cause an adverse reaction to the patient.

- For all other brand name topical acne product requests:
  - The patient has tried and failed one generic prescription topical adapalene, benzoyl peroxide, clindamycin, erythromycin, or sodium sulfacetamide containing product; OR
  - There is clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient.

(Note: The criteria for the trial and failure of other products are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met).

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Aktipak (erythromycin/benzoyl peroxide) when the patient has not tried and failed an over the counter benzoyl peroxide product for at least one month AND a separate benzoyl peroxide product and generic topical clindamycin or erythromycin product used together for at least one month AND a generic combination erythromycin/benzoyl peroxide gel or generic combination clindamycin/benzoyl peroxide gel for at least one month to be not medically necessary.**

Based on review of available data, the Company considers the use of brand name topical acne products (other than Aktipak) when the patient has NOT tried and failed one generic prescription topical adapalene, benzoyl peroxide, clindamycin, erythromycin, or sodium sulfacetamide containing product OR when there is no documentation of clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient to be not medically necessary.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.
Based on review of available data, the Company considers the use of Aktipak (erythromycin/benzoyl peroxide) for any indication other than for the treatment of acne vulgaris to be investigational.*

**Background/Overview**

Many topical acne products are available for the treatment of acne vulgaris. Benzoyl peroxide containing products are generally indicated for the treatment or prevention of mild to moderate acne vulgaris. Adapalene products are indicated for the treatment of acne. Azelaic acid is indicated for the topical treatment of mild to moderate inflammatory acne vulgaris and for the treatment of inflammatory pustules and papules of mild to moderate acne rosacea. Topical clindamycin, erythromycin, and dapsone gel are indicated for the treatment of acne vulgaris. Sulfacetamide sodium and sulfur are antimicrobial and antiseptic agents, respectively, which aid in the removal of keratin and drying of the skin. Guidelines do not prefer any of the specific brand name agents over their generically similar products for the treatment of acne.

For topical acne medications to be effective, they must be applied as directed in order to prevent the formation of new lesions. Thus, these agents should be used daily on areas of the skin prone to acne and maintenance therapy is needed to prevent recurrence.

**Rationale/Source**

The patient selection criteria presented in this policy takes into consideration clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient. Based on a review of the data, in the absence of the above mentioned caveat, there is no advantage of using a brand name topical acne product over the available generic topical acne products. Generic drugs are considered to have equal bioavailability and efficacy in comparison to brand name drugs.

Aktipak was evaluated in two controlled clinical trials. In these trials, patients with moderate to moderately severe acne vulgaris were randomized to use Aktipak (n=228), Benzamycin topical gel (n=113), and vehicle (183). Aktipak applied twice daily for 8 weeks was significantly more effective than vehicle and comparable to Benzamycin topical gel in the percent reduction in inflammatory and non-inflammatory lesion counts. Because no significant difference was seen between Aktipak and the active comparator (Benzamycin gel), there is no advantage to the use of Aktipak over the available generic alternatives.

**References**

Topical Acne Products

Policy #  00343
Original Effective Date:  02/20/2013
Current Effective Date:  03/21/2018

Policy History
Original Effective Date:  02/20/2013
Current Effective Date:  03/21/2018

02/07/2013  Medical Policy Committee review
02/20/2013  Medical Policy Implementation Committee approval. New policy.
02/06/2014  Medical Policy Committee review
02/19/2014  Medical Policy Implementation Committee approval. No change to coverage.
03/05/2015  Medical Policy Committee review
03/20/2015  Medical Policy Implementation Committee approval. No change to coverage.
03/03/2016  Medical Policy Committee review
03/16/2016  Medical Policy Implementation Committee approval. Added generic adapalene as a step 1 product.
03/02/2017  Medical Policy Committee review
03/15/2017  Medical Policy Implementation Committee approval. Removed generic erythromycin from step 1 as the brand erythromycin product is obsolete.
03/01/2018  Medical Policy Committee review
03/21/2018  Medical Policy Implementation Committee approval. Added erythromycin to step 1 because generic erythromycin product is now available; added Aktipak and Epiduo to step 2. Also separated out into step, step/PA, and PA only to address the PA added to Aktipak. Updated background and rationale.

Next Scheduled Review Date:  03/2019

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or

3. Reference to federal regulations.

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;

B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Topical Acne Products

Policy # 00343
Original Effective Date: 02/20/2013
Current Effective Date: 03/21/2018

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.